Sanofi to buy private US vaccines biotech Protein Sciences for USD 650 million

The French drugmaker Sanofi is to acquire the United States’ private vaccines biotech Protein Sciences in a treat valued around USD 750 million, in order to strengthen its vaccines dossier.

According to the provisions of the contract, the French pharma giant will pay an initial sum of USD 650 million, and remaining USD 100 million will be paid on the accomplishment of early précised milestones.

A major appeal is biotech Protein Science’s Flublok Quadrivalent Influenza Vaccine (QIV). It is the single genetically modified protein-based influenza vaccine to be sanctioned by the United States Food and Drug Administration (FDA). It got approved in October previous year.

Sanofi’s executive vice president and head of Sanofi’s vaccines division named as Sanofi Pasteur, Mr. David Loew said that the purchase of the United States’ private vaccines biotech Protein Sciences will grant us to enlarge our influenza range with the accumulation of an eggless vaccine.

Whereas from other side, US biotech’s president and chief executive Manon Cox said that they anticipate benefit for Flublok influenza vaccine from Sanofi Pasteur’s expertise, as it is part of it now.

Owing to normal regulatory approvals, the purchase deal is anticipated to be complete in the middle of the second half this year.

The reports about deal came out on following day after the French pharma giant’s, global specialty care business named as Sanofi Genzyme demonstrated data from the second phase of the controlled open clinical trial of fitusiran in patients having haemophilia A and B, with or without inhibitors. In this study, Sanofi is partnered with Alnylam.

Fitusiran is an experimental RNAi treatment aiming antithrombin for the cure of patients suffering from haemophilia A and B. Fitusiran is intended to reduce antithrombin levels with the aim of elevating adequate thrombin production on activating the clotting deluge to repair haemostasis and avoid blood loss.

The company mentioned that the trial data demonstrate that the tolerability and safety contour of the treatment remains hopeful, without any thromboembolic situations, as well as through co-introduction of substitute factor or bypassing element. Also, monthly hypodermic administration of fitusiran attained bringing down AT, gains in thrombin production, and, in a post-hoc investigative study, diminutions in the mean anticipated annualised bleeding rate (ABR) in patients with and without inhibitors.